.png)
.png)
Coulter Partners places Head of Sales North America at Pelago Bioscience
London, June 27, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with Pelago Bioscience and is pleased to announce the placement of Brian Jarecki, PhD as Head of Sales North America.
Pelago Bioscience is a Drug Discovery Research Partner supporting preclinical drug discovery and development with its unique core technology, the Cellular Thermal Shift Assay (CETSA®). CETSA® allows the assessment and quantification of target engagement under physiological conditions – unlike traditional methods, Pelago's technology doesn't require modifying the drug or protein, saving time and resources. This results in faster generation of reliable, biologically relevant data that can guide critical decision-making from early discovery to development.
Dr. Jarecki brings over 10 years of experience building and leading high-performing commercial teams in the life sciences sector. Most recently, he played a key role in the growth and successful IPO of IsoPlexis, a single-cell proteomics company, and its subsequent acquisitions by Berkeley Lights and Bruker. With a strong scientific background and a passion for fostering innovation, he excels at driving commercial success in the field of translational research.
Chief Executive Officer and Co-founder, Michael Dabrowski commented: “I am truly excited that Brian decided to join us at Pelago Bioscience and I am very much looking forward to join him in engaging with new and existing clients in North America. Brian brings a wealth of operational and strategic experience in commercializing disruptive technologies and services to the drug discovery market. His experience will be invaluable for Pelago Bioscience as we now scale up to meet increasing customer demand in both biotech and pharma. We are on a mission to ensure that all drug discovery projects know their targets before entering clinical trials and with Brian now on board we are well under way already!”
He commented on his experience working with Coulter Partners: “We were truly impressed by the Coulter Partners team's professionalism and the caliber of candidates they presented to us. What really stood out, though, was their agility. They truly understood our unique need for a senior commercial leader who could hit the ground running and wasn't afraid to get hands-on. They delivered exactly what we were looking for.”
Commenting on his appointment, Brian Jarecki added: “I am beyond thrilled to join the team at Pelago Bioscience and work shoulder-to-shoulder with our growth-mindset teammates and investors to ensure the company continues to expand and support the growing demands within the drug discovery paradigm from preclinical target engagement into the clinic. Leveraging our patented CETSA® (Cellular Thermal Shift Assay) platform, our expert team have already laid a strong foundation in the market as Pelago enters its next chapter of high growth and development. The enthusiasm and dedication across all teams to our company mission and focus on building the best relationships in the industry have been truly inspirational and I look forward to helping Pelago for many years to come.”
Coulter Partners shapes the future of groundbreaking organizations by building high-performing leadership teams. Its global team of exceptional and diverse specialists – with expertise in leadership, science, technology, finance, and innovation – connects the most pioneering talent in Health, Science, and Technology, ultimately helping these organizations deliver a better future.
----
Dr. Brian Jarecki, Head of Sales North America
Brian Jarecki has spent the past 10+ years working for several disruptive biotechnology companies in the life sciences space as part of their commercial growth teams with private, venture capital, and private equity backing. For the past 5 1/2 years he has held several commercial leadership roles, most recently as Vice President of North America Sales at IsoPlexis (NASDAQ: ISO), the single-cell functional proteomics company, where he helped build, train, and grow a high-functioning commercial team from pre-revenue Series B to IPO (USD $125M). Over the past year, he has helped navigate the team through two M&A deals with Berkeley Lights, to form PhenomeX (NASDAQ: CELL), and Bruker (NASDAQ: BRKR) as part of their BNANO Cellular Analysis Division build-out.
Before his work at IsoPlexis, Brian worked for high-growth commercial teams at Essen Bioscience (eventually acquired by Sartorius as part of their Bioanalytics Division build-out), and Cellular Dynamics (NASDAQ: CDI), which FUJIFILM ultimately acquired as part of their multi-billion-dollar investment in stem cell therapy and manufacturing. With a Ph.D. in Pharmacology and Toxicology and a Postdoctoral Fellowship in Neuroscience and Biophysics, he is well-published in the scientific field and prides himself on being a consultative servant-leader with a passion for building high-achieving commercial teams that support global life sciences efforts in advancing translational research and innovation.
Pelago Bioscience is a Drug Discovery Research Partner supporting preclinical drug discovery and development with its unique core technology, the Cellular Thermal Shift Assay (CETSA®). CETSA® allows the assessment and quantification of target engagement under physiological conditions – unlike traditional methods, Pelago's technology doesn't require modifying the drug or protein, saving time and resources. This results in faster generation of reliable, biologically relevant data that can guide critical decision-making from early discovery to development.
Dr. Jarecki brings over 10 years of experience building and leading high-performing commercial teams in the life sciences sector. Most recently, he played a key role in the growth and successful IPO of IsoPlexis, a single-cell proteomics company, and its subsequent acquisitions by Berkeley Lights and Bruker. With a strong scientific background and a passion for fostering innovation, he excels at driving commercial success in the field of translational research.
Chief Executive Officer and Co-founder, Michael Dabrowski commented: “I am truly excited that Brian decided to join us at Pelago Bioscience and I am very much looking forward to join him in engaging with new and existing clients in North America. Brian brings a wealth of operational and strategic experience in commercializing disruptive technologies and services to the drug discovery market. His experience will be invaluable for Pelago Bioscience as we now scale up to meet increasing customer demand in both biotech and pharma. We are on a mission to ensure that all drug discovery projects know their targets before entering clinical trials and with Brian now on board we are well under way already!”
He commented on his experience working with Coulter Partners: “We were truly impressed by the Coulter Partners team's professionalism and the caliber of candidates they presented to us. What really stood out, though, was their agility. They truly understood our unique need for a senior commercial leader who could hit the ground running and wasn't afraid to get hands-on. They delivered exactly what we were looking for.”
Commenting on his appointment, Brian Jarecki added: “I am beyond thrilled to join the team at Pelago Bioscience and work shoulder-to-shoulder with our growth-mindset teammates and investors to ensure the company continues to expand and support the growing demands within the drug discovery paradigm from preclinical target engagement into the clinic. Leveraging our patented CETSA® (Cellular Thermal Shift Assay) platform, our expert team have already laid a strong foundation in the market as Pelago enters its next chapter of high growth and development. The enthusiasm and dedication across all teams to our company mission and focus on building the best relationships in the industry have been truly inspirational and I look forward to helping Pelago for many years to come.”
Coulter Partners shapes the future of groundbreaking organizations by building high-performing leadership teams. Its global team of exceptional and diverse specialists – with expertise in leadership, science, technology, finance, and innovation – connects the most pioneering talent in Health, Science, and Technology, ultimately helping these organizations deliver a better future.
----
Dr. Brian Jarecki, Head of Sales North America
Brian Jarecki has spent the past 10+ years working for several disruptive biotechnology companies in the life sciences space as part of their commercial growth teams with private, venture capital, and private equity backing. For the past 5 1/2 years he has held several commercial leadership roles, most recently as Vice President of North America Sales at IsoPlexis (NASDAQ: ISO), the single-cell functional proteomics company, where he helped build, train, and grow a high-functioning commercial team from pre-revenue Series B to IPO (USD $125M). Over the past year, he has helped navigate the team through two M&A deals with Berkeley Lights, to form PhenomeX (NASDAQ: CELL), and Bruker (NASDAQ: BRKR) as part of their BNANO Cellular Analysis Division build-out.
Before his work at IsoPlexis, Brian worked for high-growth commercial teams at Essen Bioscience (eventually acquired by Sartorius as part of their Bioanalytics Division build-out), and Cellular Dynamics (NASDAQ: CDI), which FUJIFILM ultimately acquired as part of their multi-billion-dollar investment in stem cell therapy and manufacturing. With a Ph.D. in Pharmacology and Toxicology and a Postdoctoral Fellowship in Neuroscience and Biophysics, he is well-published in the scientific field and prides himself on being a consultative servant-leader with a passion for building high-achieving commercial teams that support global life sciences efforts in advancing translational research and innovation.